# Evaluation of Nasal Biomarkers for Objective Assessment of Disease Severity in Respiratory Disorders

> **NCT06661252** · — · COMPLETED · sponsor: **Diag-Nose Medical Pty Ltd** · enrollment: 111 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)
- Asthma Patients
- Asthma and Rhinitis
- Asthmatic Patients
- Asthma, Chronic Obstructive Pulmonary Disease (COPD)
- Rhinitis Allergic
- Rhinitis, Allergic, Perennial and/or Seasonal
- Non-allergic Rhinitis
- Chronic Sinusitis With or Without Nasal Polyps
- Healthy Volunteers

## Interventions

- **DEVICE:** ABEL microsampler device

## Key facts

- **NCT ID:** NCT06661252
- **Lead sponsor:** Diag-Nose Medical Pty Ltd
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2025-01-08
- **Primary completion:** 2025-11-25
- **Final completion:** 2025-11-25
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06661252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06661252, "Evaluation of Nasal Biomarkers for Objective Assessment of Disease Severity in Respiratory Disorders". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06661252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*